Anti-L-selectin monoclonal antibodies - PDL BioPharma

Drug Profile

Anti-L-selectin monoclonal antibodies - PDL BioPharma

Alternative Names: Anti-L-selectin monoclonal antibody DREG 200 - PDL BioPharma; Anti-L-selectin monoclonal antibody DREG 55; Aselizumab; BNP 001; DREG 200 - PDL BioPharma; DREG 55; hDREG-200 - PDL BioPharma; hDREG-55; Hu DREG 55; SMART anti-L-selectin antibodies

Latest Information Update: 24 May 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PDL BioPharma
  • Class Monoclonal antibodies
  • Mechanism of Action L-selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Shock
  • Discontinued Adult respiratory distress syndrome; Crohn's disease; Psoriasis; Reperfusion injury

Most Recent Events

  • 22 May 2006 No development reported - Preclinical for Shock in USA (unspecified route)
  • 09 Jan 2006 Protein Design Labs is now called PDL BioPharma
  • 18 Aug 2005 Data presented at the 66th Annual Meeting of the Society for Investigative Dermatology (SID-2005) have been added to the Skin disorders therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top